ReviewNew paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
Under a Creative Commons license
open access
Abbreviations
AE2
anion exchanger 2
ASBT
apical sodium bile salt transporter
BA
bile acid
CA
cholic acid
CDCA
chenodeoxycholic acid
CFALD
cystic fibrosis-associated liver disease
CFTR
cystic fibrosis transmembrane conductance regulator
DCA
deoxycholic acid
FGF
fibroblast growth factor
FXR
farnesoid X receptor
GR
glucocorticoid receptor
IBD
inflammatory bowel disease
ICP
intrahepatic cholestasis of pregnancy
LCA
lithocholic acid
LPAC
low phospholipid-associated cholelithiasis
MAPK
mitogen-activated protein kinase
NAFLD
non-alcoholic fatty liver disease
NASH
non-alcoholic steatohepatitis
PBC
primary biliary cirrhosis
PFIC
progressive familial intrahepatic cholestasis
PKA
protein kinase A
PKC
protein kinase C
PPARα
peroxisome proliferator-activated receptor α
PSC
primary sclerosing cholangitis
PXR
pregnane X receptor
UDCA
ursodeoxycholic acid
VDR
vitamin D receptor
Keywords
UDCA
FXR
PXR
Cholestasis
Cited by (0)
© 2015 European Association for the Study of the Liver. Published by Elsevier B.V.